FINANCIAL HIGHLIGHTS Six months ended 30 June 2026 2025 Change RMB million RMB million (Unaudited) (Unaudited) 8,695.9 1,583.3 1,891.9 21.8% 610.6 919.2 10.6% Revenue EBITDA* Adjusted EBITDA* Adjusted EBITDA margin Net profit Adjusted net profit**…
FINANCIAL HIGHLIGHTS
Six months ended 30 June
2026
2025
Change
RMB million
RMB million
(Unaudited)
(Unaudited)
8,695.9
1,583.3
1,891.9
21.8%
610.6
919.2
10.6%
Revenue
EBITDA*
Adjusted EBITDA*
Adjusted EBITDA margin
Net profit
Adjusted net profit**
Adjusted net profit margin
7,019.2
1,033.1
1,100.7
15.7%
71.0
363.0
5.2%
+23.9%
+53.3%
+71.9%
+6.1pts
+760.0%
+153.2%
+5.4pts
EBITDA refers to earnings before interest, income tax expense, depreciation and amortization. Adjusted
EBITDA = EBITDA + Non-cash losses of RMB308.6 million for the six months ended 30 June 2026
(six months ended 30 June 2025: losses of RMB57.6 million) + Non-recurring losses of nil for the six
months ended 30 June 2026 (six months ended 30 June 2025: losses of RMB10.0 million)
**
Adjusted net profit = Net profit + EBITDA adjustment items of losses of RMB308.6 million for the six
months ended 30 June 2026 (six months ended 30 June 2025: losses of RMB67.6 million) + Other noncash losses of nil for the six months ended 30 June 2026 (six months ended 30 June 2025: losses of
RMB224.4 million)
–1–
The board (the “Board”) of directors (the “Directors”) of Health and Happiness (H&H)
International Holdings Limited (the “Company”) is pleased to announce the unaudited interim
consolidated results of the Company and its subsidiaries (together, the “Group”) for the six
months ended 30 June 2026, together with the comparative figures for the corresponding
period in 2025, as follows:
INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME
Six months ended 30 June 2026
Notes
5
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
8,695,910
7,019,234
Cost of sales
(3,009,906)
(2,630,154)
Gross profit
5,686,004
4,389,080
36,276
(3,400,653)
(443,763)
(404,083)
(311,927)
(33,370)
61,751
(2,971,278)
(398,526)
(181,731)
(579,542)
(13,462)
1,128,484
(517,855)
306,292
(235,275)
610,629
71,017
(43,461)
(13,245)
19,634
33,783
14,467
133,058
(9,360)
153,596
REVENUE
5
Other income and gains
Selling and distribution expenses
Administrative expenses
Other expenses
Finance costs
Share of losses of associates
PROFIT BEFORE TAX
Income tax expense
6
PROFIT FOR THE PERIOD
OTHER COMPREHENSIVE INCOME/(LOSS)
Other comprehensive (loss)/income that may be
reclassified to profit or loss in subsequent periods:
Hedge of net investments:
Effective portion of changes in fair value of hedging
instruments arising during the period
Exchange differences on translation of foreign
operations
Exchange differences on net investment in foreign
operations
Net other comprehensive (loss)/income that may be
reclassified to profit or loss in subsequent periods
–2–
INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME (continued)
Six months ended 30 June 2026
Note
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Other comprehensive (loss)/income that will not be
reclassified to profit or loss in subsequent periods:
Changes in fair value of equity investments
designated at fair value through other
comprehensive income
(4,885)
781
OTHER COMPREHENSIVE (LOSS)/INCOME
FOR THE PERIOD, NET OF TAX
(14,245)
154,377
TOTAL COMPREHENSIVE INCOME
FOR THE PERIOD
596,384
225,394
Profit attributable to owners of the parent
610,629
71,017
Total comprehensive income attributable to
owners of the parent
596,384
225,394
RMB
(Unaudited)
RMB
(Unaudited)
Basic
0.95
0.11
Diluted
0.95
0.11
EARNINGS PER SHARE ATTRIBUTABLE TO
ORDINARY EQUITY HOLDERS OF THE
PARENT
–3–
8
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
30 June 2026
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
NON-CURRENT ASSETS
Property, plant and equipment
Right-of-use assets
Goodwill
Intangible assets
Deposits
Investments in associates
Deferred tax assets
Derivative financial instruments
Other non-current financial assets
300,970
196,313
7,534,316
4,908,634
509,639
57,843
568,146
17,509
143,404
302,820
217,778
7,620,614
5,063,903
32,761
91,213
546,752
40,470
190,858
Total non-current assets
14,236,774
14,107,169
1,982,430
1,025,155
247,863
16,552
120,150
1,856,301
1,968,079
904,245
697,673
17,357
40,000
1,669,001
5,248,451
5,296,355
1,069,055
2,508,288
42,037
44,365
1,722,099
27,701
80,868
448,772
89,206
1,007,982
2,302,762
36,989
7,445
995,137
29,548
83,656
151,919
–
Total current liabilities
6,032,391
4,615,438
NET CURRENT (LIABILITIES)/ASSETS
(783,940)
680,917
Notes
CURRENT ASSETS
Inventories
Trade receivables
Prepayments, other receivables and other assets
Pledged deposits
Time deposits
Cash and cash equivalents
9
Total current assets
CURRENT LIABILITIES
Trade and bills payables
Other payables and accruals
Contract liabilities
Derivative financial instruments
Interest-bearing bank loans and other borrowings
Lease liabilities
Senior notes
Tax payable
Dividend payable
–4–
10
11
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
(continued)
30 June 2026
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
TOTAL ASSETS LESS CURRENT LIABILITIES
13,452,834
14,788,086
NON-CURRENT LIABILITIES
Senior notes
Interest-bearing bank loans and other borrowings
Other payables and accruals
Lease liabilities
Derivative financial instruments
Deferred tax liabilities
2,017,639
3,760,989
3,645
112,356
309,316
735,113
2,074,993
5,740,336
4,376
127,255
160,126
690,138
Total non-current liabilities
6,939,058
8,797,224
Net assets
6,513,776
5,990,862
EQUITY
Issued capital
Reserves
Proposed dividend
5,519
6,508,257
–
5,519
5,894,531
90,812
Total equity
6,513,776
5,990,862
Note
–5–
11
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
Six months ended 30 June 2026
Note
CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax
Adjustments for:
Bank interest income
Finance costs
Share of losses of associates
Loss on disposal of other non-current
financial assets
Depreciation of property, plant and equipment
Depreciation of right-of-use assets
Amortisation of intangible assets
Loss on disposal of items of property, plant and
equipment and intangible assets
Equity-settled share option expense
Equity-settled share award expense
Fair value losses on derivative financial instruments,
net
Fair value losses/(gains) on other non-current
financial assets
(Reversal of impairment)/impairment of trade
receivables
Write-down of inventories to net realisable value
Foreign exchange losses/(gains), net
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
1,128,484
306,292
(7,545)
311,927
33,370
(6,335)
579,542
13,462
454
25,710
22,912
101,845
–
33,082
19,989
100,517
336
16,233
–
65
–
344
154,889
74,053
37,906
(5,524)
(2,207)
134,494
82,430
289
206,514
(24,361)
2,041,238
1,297,929
Increase in inventories
Increase in trade receivables
Increase in prepayments, other receivables and
other assets
Decrease/(increase) in rental deposits
Decrease/(increase) in restricted deposits
Increase in trade and bills payables
Increase in other payables and accruals
Increase in contract liabilities
(150,492)
(234,311)
(205,570)
(190,538)
(37,128)
2,050
805
61,360
202,746
4,825
(21,860)
(342)
(9,717)
52,076
165,622
15,651
Cash generated from operations
Corporate income tax paid
1,891,093
(196,003)
1,103,251
(105,218)
Net cash flows from operating activities
1,695,090
998,033
–6–
5
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(continued)
Six months ended 30 June 2026
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
1,695,090
998,033
(28,416)
(9,978)
(24,281)
(16,710)
2,348
425
(80,150)
(4,285)
860
7,545
–
–
–
9,181
(112,076)
(31,385)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issue of senior notes
Payment of transaction costs for issue of senior notes
Repurchase and redemption of senior notes
Repayment of interest-bearing bank loans
New bank loans
Payment of lease liabilities
Interest paid
Proceeds from the swaps
Proceeds from termination of certain swaps
Settlement for termination of forward contracts
–
–
–
(1,337,980)
250,000
(23,057)
(271,417)
24,735
–
(8,751)
2,111,651
(28,685)
(2,334,058)
(266,297)
50,000
(23,823)
(244,430)
9,504
19,604
–
Net cash flows used in financing activities
(1,366,470)
(706,534)
Net cash flows from operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of items of property, plant and equipment
Purchases of items of intangible assets
Proceeds from disposal of items of property,
plant and equipment and intangible assets
Placement of time deposits with original maturity of
three months or more when acquired
Addition to other non-current financial assets
Proceeds from disposal of certain financial assets
Interest received
Net cash flows used in investing activities
–7–
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(continued)
Six months ended 30 June 2026
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
NET INCREASE IN CASH AND CASH EQUIVALENTS
Cash and cash equivalents at beginning of the period
Effect of foreign exchange rate changes, net
216,544
1,669,001
(29,244)
260,114
1,603,920
(52,010)
CASH AND CASH EQUIVALENTS AT END
OF THE PERIOD
1,856,301
1,812,024
ANALYSIS OF BALANCES OF CASH AND
CASH EQUIVALENTS
Cash and bank balances
1,856,301
1,812,024
Cash and cash equivalent as stated in the interim condensed
consolidated statement of financial position and interim
condensed consolidated statement of cash flows
1,856,301
1,812,024
–8–
NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30 June 2026
1.
CORPORATE AND GROUP INFORMATION
Health and Happiness (H&H) International Holdings Limited (the “Company”) was incorporated as
an exempted company with limited liability in the Cayman Islands. The registered office address of the
Company is Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman KY1-1111, Cayman Islands.
The Company and its subsidiaries (together, the “Group”) are principally engaged in the manufacture
and sale of premium pediatric nutrition and baby care products, adult nutrition and care products and pet
nutrition and care products.
In the opinion of the directors, the holding company and the ultimate holding company of the Company is
Coliving Holdings Limited, a limited liability company incorporated in the British Virgin Islands.
BASIS OF PREPARATION AND ACCOUNTING POLICIES
These unaudited interim condensed consolidated financial statements of the Group for the six months
ended 30 June 2026 have been prepared in accordance with International Accounting Standard (“IAS”)
34 Interim Financial Reporting issued by the International Accounting Standards Board. These unaudited
interim condensed consolidated financial statements are presented in Renminbi (“RMB”) and all values
are rounded to the nearest thousand except when otherwise indicated.
The accounting policies and basis of preparation used in the preparation of these unaudited interim
condensed consolidated financial statements are the same as those used in the Group’s annual consolidated
financial statements for the year ended 31 December 2025, except for the adoption of the amended IFRS
Accounting Standards as disclosed in note 3 below.
These unaudited interim condensed consolidated financial statements do not include all information
and disclosures required in the Group’s annual consolidated financial statements, and should be read in
conjunction with the Group’s annual consolidated financial statements for the year ended 31 December
2025.
CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES
The accounting policies adopted in the preparation of the interim condensed consolidated financial
information are consistent with those applied in the preparation of the Group’s annual consolidated
financial statements for the year ended 31 December 2025, except for the adoption of the following
amended IFRS Accounting Standards for the first time for the current period’s financial information:
Amendments to IFRS 9 and IFRS 7
Amendments to IFRS 9 and IFRS 7
Annual Improvements to IFRS Accounting
Standards – Volume 11
Amendments to the Classification and Measurement of
Financial Instrument
Contracts Referencing Nature-dependent Electricity
Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10
and IAS 7
–9–
OPERATING SEGMENT INFORMATION
For management purposes, the Group is organised into business units based on their products, and has five
reportable operating segments as follows:
(a)
the adult nutrition and care products segment comprises the production and sale of vitamins, herbal
and mineral supplements, skin care and sports nutrition products for adults;
(b)
the infant formulas segment comprises the production and sale of milk formulas for infants, children
and expectant and nursing mothers;
(c)
the pet nutrition and care products segment comprises the production and sale of holistic pet food
and multi-condition pet supplements;
(d)
the paediatric probiotic and kids nutritional supplements segment comprises the production and
sale of probiotic supplements and nutrition supplements in the form of powder, sachets, capsules,
gummies and tablets for infants, children and expectant mothers; and
(e)
the other pediatric products segment comprises the production and sale of dried baby food and baby
care products.
Management monitors the results of the Group’s operating segments separately for the purpose of making
decisions about resource allocation and performance assessment. Segment performance is evaluated based
on reportable segment profit which is measured consistently with the Group’s profit before tax except that
interest income, other income and unallocated gains, share of results of associates, finance costs as well as
head office and corporate expenses are excluded from this measurement.
– 10 –
Operating segment information for the six months ended 30 June 2026 (Unaudited):
Segment revenue:
Sales to external customers
Segment results
Reconciliations:
Interest income
Other income and unallocated gains
Share of losses of associates
Corporate and other unallocated expenses
Finance costs
Adult
nutrition
and care
products
RMB’000
Infant
formulas
RMB’000
Pet
Probiotic
nutrition
and
and care nutritional
products supplements
RMB’000
RMB’000
Other
pediatric
products Unallocated
RMB’000
RMB’000
Total
RMB’000
3,973,074
3,093,047
1,090,366
433,351
106,072
–
8,695,910
2,787,218
1,857,469
665,876
332,570
42,871
–
5,686,004
7,545
28,731
(33,370)
(4,248,499)
(311,927)
1,128,484
Profit before tax
Other segment information:
Depreciation and amortisation
42,569
14,397
44,284
3,289
2,370
43,558
150,467
Impairment/(reversal of impairment) of
trade receivables
1,640
–
–
–
(3,847)
–
(2,207)
Write-down of inventories to
net realisable value
24,231
84,270
3,227
456
22,310
–
134,494
Capital expenditure*
6,773
14,090
10,498
1,741
2,121
11,593
46,816
– 11 –
Operating segment information for the six months ended 30 June 2025 (Unaudited):
Segment revenue:
Sales to external customers
Segment results
Reconciliations:
Interest income
Other income and unallocated gains
Share of losses of associates
Corporate and other unallocated expenses
Finance costs
Adult
nutrition
and care
products
RMB’000
Infant
formulas
RMB’000
Pet
Probiotic
nutrition
and
and care nutritional
products supplements
RMB’000
RMB’000
Other
pediatric
products Unallocated
RMB’000
RMB’000
Total
RMB’000
3,438,722
1,970,973
1,079,202
427,224
103,113
–
7,019,234
2,322,496
1,092,323
633,556
297,001
43,704
–
4,389,080
6,335
55,416
(13,462)
(3,551,535)
(579,542)
Profit before tax
306,292
Other segment information:
Depreciation and amortisation
39,348
14,877
41,358
3,399
4,774
49,832
153,588
Impairment of trade receivables
289
–
–
–
–
–
289
Write-down of inventories to
net realisable value
37,592
115,779
5,301
41,775
6,067
–
206,514
Capital expenditure*
18,361
31,920
3,804
3,095
2,474
6,222
65,876
Capital expenditure consists of additions to property, plant and equipment and intangible assets
including assets from the acquisition of subsidiaries.
Geographical information
(a)
Revenue from external customers
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Chinese mainland*
Australia and New Zealand
North America
Other locations#
6,462,475
771,681
956,644
505,110
4,936,033
800,718
862,155
420,328
Total revenue
8,695,910
7,019,234
Including the cross-border e-commerce sales through the subsidiaries registered in Hong
Kong Special Administrative Region (“Hong Kong SAR”) of the People’s Republic of China
(the “PRC”) to customers in Chinese mainland.
The revenue information above is based on the locations of the customers.
– 12 –
(b)
Non-current assets
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
Chinese mainland
Australia and New Zealand
North America
Other locations#
63,779
2,649,265
2,223,283
1,037,072
88,809
2,207,611
2,329,894
1,082,161
Total non-current assets
5,973,399
5,708,475
The non-current assets information above is based on the locations of the assets and excludes
financial instruments, deferred tax assets and goodwill.
Including the special administrative regions of the PRC and Taiwan of the PRC.
REVENUE, OTHER INCOME AND GAINS
Revenue
An analysis of the revenue is as follows:
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Revenue from contracts with customers
Sale of goods
8,695,910
7,019,234
Disaggregated revenue information
For the six months ended 30 June 2026 (unaudited)
Adult
nutrition
and care
products
RMB’000
Chinese mainland
Australia and New Zealand
North America
Other locations*
Total
Segments
Infant
formulas
RMB’000
Pet
Probiotic
nutrition
and
and care nutritional
products supplements
RMB’000
RMB’000
Other
pediatric
products
RMB’000
Total
RMB’000
2,900,516
762,522
16,074
293,962
3,010,766
7,273
–
75,008
127,728
986
939,027
22,625
423,408
900
1,543
7,500
57
–
–
106,015
6,462,475
771,681
956,644
505,110
3,973,074
3,093,047
1,090,366
433,351
106,072
8,695,910
3,973,074
3,093,047
1,090,366
433,351
106,072
8,695,910
Geographical markets
Timing of revenue recognition
Goods transferred at a point in time
– 13 –
For the six months ended 30 June 2025 (unaudited)
Adult
nutrition
and care
products
RMB’000
Chinese mainland
Australia and New Zealand
North America
Other locations*
Total
Segments
Infant
formulas
RMB’000
Pet
nutrition
and care
products
RMB’000
Probiotic
and
nutritional
supplements
RMB’000
Other
pediatric
products
RMB’000
Total
RMB’000
2,406,085
788,692
11,700
232,245
1,904,945
11,494
–
54,534
204,873
–
849,985
24,344
419,689
532
462
6,541
441
–
8
102,664
4,936,033
800,718
862,155
420,328
3,438,722
1,970,973
1,079,202
427,224
103,113
7,019,234
3,438,722
1,970,973
1,079,202
427,224
103,113
7,019,234
Geographical markets
Timing of revenue recognition
Goods transferred at a point in time
*
Including the special administrative regions of the PRC and Taiwan of the PRC.
Other income and gains
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Bank interest income
Foreign exchange gains
Fair value gains on other non-current financial assets
Government subsidies*
Gains on sales of raw materials and scraps
Others
7,545
–
–
652
11,162
16,917
6,335
24,361
5,524
363
13,940
11,228
Total other income and gains
36,276
61,751
There are no unfulfilled conditions or contingencies related to these government subsidies.
– 14 –
INCOME TAX EXPENSE
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Current
– Charge for the period
Chinese mainland
Hong Kong SAR
Australia
Elsewhere
– Under/(over) provision in the prior year
Deferred
199,838
196,337
49,352
31,931
15,518
24,879
91,490
58,873
51,834
382
(1,616)
34,312
Total
517,855
235,275
The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions
in which members of the Group are domiciled and operate.
PRC enterprise income tax (“EIT”)
The income tax provision of the Group in respect of its operations in Chinese mainland has been calculated
at the rate of 25% (six months ended 30 June 2025: 25%) on the taxable profits for the period, based on
the existing legislation, interpretations and practices in respect thereof.
Certain of the Group’s subsidiaries in Chinese mainland are qualified as high and new technology
enterprises and are entitled to a preferential corporate income tax rate of 15% during the relevant periods.
Hong Kong profits tax
Hong Kong profits tax has been provided at the rate of 16.5% (six months ended 30 June 2025: 16.5%) on
the estimated assessable profits arising in Hong Kong during the period, except for one subsidiary of the
Group which is a qualifying entity under the two-tiered profits tax rates regime. The first HKD2,000,000
(six months ended 30 June 2025: HKD2,000,000) of assessable profits of this subsidiary is taxed at 8.25%
(six months ended 30 June 2025: 8.25%) and the remaining assessable profits are taxed at 16.5% (six
months ended 30 June 2025: 16.5%).
Australia corporate income tax
Australia corporate income tax has been provided at the rate of 30% (six months ended 30 June 2025:
30%) on the estimated assessable profits arising in Australia.
Tax consolidation legislation
Biostime Healthy Australia Pty Ltd. (“BHA”), its wholly-owned Australian subsidiaries and eligible Tier
1 fellow subsidiary have elected to form an income tax multiple entry consolidated (“MEC”) group, for
Australian income tax purposes.
In an income tax MEC group, BHA, its wholly-owned subsidiaries and eligible Tier 1 fellow subsidiary
within the income tax MEC group account for their own current and deferred tax amounts. These income
tax amounts are measured as if each entity in the income tax MEC group continues to be a standalone
taxpayer in its own right.
– 15 –
In addition to its own current and deferred tax amounts, BHA also recognises the current tax liabilities
(or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from
subsidiaries within the income tax MEC group.
The entities have also entered into a tax funding arrangement under which the wholly-owned entities fully
compensate BHA for any current tax payable assumed and are compensated by BHA for any current tax
receivable and deferred tax assets relating to unused tax losses or unused tax credits that are transferred to
BHA under the income tax consolidation legislation. The funding amounts are determined by reference to
the amounts recognised in the wholly-owned entities’ financial statements.
The amounts receivable/payable under the tax funding arrangement are due upon receipt of the funding
advice from the head entity, which is issued as soon as practicable after the end of each financial year. The
head entity may also require payment of interim funding amounts to assist with its obligations to pay tax
instalments.
Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as
current amounts receivable from or payable to other entities in the Group.
Any difference between the amounts assumed and amounts receivable or payable under the tax funding
agreement are recognised as a contribution to (or distribution from) wholly-owned tax consolidated
entitles.
Income tax for other jurisdictions
The Group’s tax provision in respect of other jurisdictions has been calculated at the applicable tax rates
in accordance with the prevailing practices of the jurisdictions in which the Group operates.
Pillar Two income taxes
The Group is within the scope of the Pillar Two model rules. The Group has assessed its potential
exposure based on the information available regarding the financial performance of the Group in the
current period. As such, it may not be entirely representative of future circumstances.
Based on the assessment, transitional safe harbor may apply on all the jurisdictions where Pillar
Two legislation is in effect during the current period. The management is not currently aware of any
circumstances under which this might change. The Group does not expect a material exposure to Pillar
Two income taxes. The Group continues to follow Pillar Two legislative developments, as more countries
prepare to enact the Pillar Two model rules, to evaluate the potential future impact on its financial
statements.
7.
DIVIDENDS
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Final declared – HKD0.16 (2025: HKD0.05) per ordinary share
89,703
29,732
Dividends on ordinary shares declared after the interim reporting date:
Interim – HKD0.82 (2025: HKD0.19) per ordinary share
459,612
108,893
On 25 August 2026, the board of directors of Health and Happiness (H&H) International Holdings
Limited declared an interim dividend of HKD0.82 (six months ended 30 June 2025: HKD0.19) per
ordinary share, amounting to a total of approximately RMB459,612,000 (six months ended 30 June 2025:
RMB108,893,000).
– 16 –
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE
PARENT
The calculation of the basic earnings per share amount is based on the profit for the six months ended 30
June 2026 attributable to ordinary equity holders of the parent of RMB610,629,000 (six months ended 30
June 2025: RMB71,017,000), and the adjusted weighted average number of ordinary shares of 641,778,731
(six months ended 30 June 2025: 641,662,090) outstanding during the period.
The calculation of the diluted earnings per share amount for the period is based on the profit for the period
attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares
used in the calculation of diluted earnings per share is the adjusted weighted average number of ordinary
shares outstanding during the period, as used in the basic earnings per share calculation, and the weighted
average number of ordinary shares assumed to have been issued at no consideration on the deemed
exercise of all dilutive potential ordinary shares into ordinary shares under the share option schemes and
the share award schemes. No adjustment had been made to the basic earnings per share amount presented
for the six months ended 30 June 2026 in respect of a dilution as impact of the potential ordinary shares
had an anti-dilutive effect on the basic earnings per share amount presented.
The calculations of the basic and diluted earnings per share are based on:
Six months ended 30 June
2026
2025
RMB’000
RMB’000
(Unaudited)
(Unaudited)
Earnings
Profit attributable to ordinary equity holders of the parent,
used in the basic earnings per share calculation
610,629
71,017
Number of shares
Shares
Weighted average number of ordinary shares outstanding
645,561,354
645,561,354
Weighted average number of shares held for the share award schemes
(3,782,623)
(3,899,264)
Adjusted weighted average number of ordinary shares outstanding used in
the basic earnings per share calculation
641,778,731
641,662,090
Effect of dilution – weighted average number of ordinary shares:
Share options and awarded shares
–
116,646
Adjusted weighted average number of ordinary shares outstanding
used in the diluted earnings per share calculation
641,778,731
641,778,736
TRADE RECEIVABLES
An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date
and net of provisions, is as follows:
Within 1 month
1 to 3 months
Over 3 months
Total
– 17 –
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
566,389
370,953
87,813
472,122
381,204
50,919
1,025,155
904,245
TRADE AND BILLS PAYABLES
An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the
invoice date, is as follows:
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
893,794
139,805
35,456
841,635
134,390
31,957
1,069,055
1,007,982
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
216,301
1,281,212
97,132
281,394
635,894
214,687
1,103,804
53,210
326,384
609,053
Total
2,511,933
2,307,138
Less: current portion
(2,508,288)
(2,302,762)
Non-current portion
3,645
4,376
Within 1 month
1 to 3 months
Over 3 months
Total
11.
OTHER PAYABLES AND ACCRUALS
Notes
Salaries and welfare payables
Accruals
Other tax payables
Other payables
Refund liabilities
(a)
(b)
Notes:
(a)
Other payables are non-interest-bearing and have an average term of three months.
(b)
Details of refund liabilities as at 30 June 2026 and 31 December 2025 are as follows:
30 June
2026
RMB’000
(Unaudited)
31 December
2025
RMB’000
(Audited)
Sales rebate
Sales return
619,769
16,125
598,116
10,937
Total
635,894
609,053
– 18 –
CHAIRMAN’S STATEMENT
The Group delivered a strong first half, underpinned by strong momentum across all our three
business segments: Adult Nutrition and Care (the “ANC”), Baby Nutrition and Care (the
“BNC”) and Pet Nutrition and Care (the “PNC”). Crucially, our results demonstrate how each
of our business segments is unlocking or creating long-term structural drivers that will support
the sustainability of our growth trajectory.
Key highlights in the first half of 2026 included:
•
Strong growth with healthy profitability: Total revenue increased by 23.7% on a likefor-like (the “LFL”) basis, driven by growth across all business segments. High-margin
nutritional supplements accounted for 60.2% of revenue. Adjusted EBITDA grew by
71.9% and adjusted EBITDA margin reached 21.8%, thanks to marketing investment
phasing and improved cost efficiency. We will continue to step up investment in new
strategic product launches and in initiatives targeting our core markets and selected
expansion markets in the second half to support our sustainable growth.
•
ANC delivered broad-based growth across core and expansion markets: ANC
revenue grew by 13.9% on a LFL basis, supported by continued momentum in Chinese
mainland, the Australia and New Zealand (the “ANZ”) domestic market, and expansion
markets including Thailand, Middle East and India (the “MEI”), Indonesia and
Malaysia.
•
BNC growth accelerated on sustained market-share gains and structural
growth drivers: BNC revenue grew by 45.2%, driven by 58.0% growth in infant
milk formulas (the “IMF”) sales in Chinese mainland. Continued investment in new
mother education, improving Stage 3 conversion and product innovation strengthened
consumer engagement and supported sustained market-share gains, while recent industry
developments provided an additional tailwind. Our market share in the super-premium
IMF segment in Chinese mainland increased to 20.6%, up from 14.8% a year earlier1.
•
PNC continued to build scale, led by high-margin pet supplements: PNC revenue
grew by 4.8% on a LFL basis, supported by accelerated growth of 16.5% in the highmargin pet supplements category and channel expansion in North America.
•
Balance sheet continued to strengthen: In the first half of 2026, we reduced gross debt
by over RMB1 billion, reducing our net leverage ratio from 3.45x as of 31 December
2025 to 2.05x as of 30 June 2026, accelerating our deleveraging trajectory while
maintaining healthy cash reserves of close to RMB2.0 billion.
We remain committed to maintaining a steady track record of dividend payouts, in addition
to steadily reducing our leverage and further improving our balance sheet. In line with this
commitment, I am pleased to announce an interim dividend of HKD0.82 per ordinary share.
1
According to research statistics by Nielsen, an independent research company, market share data for the
past twelve months ended 30 June 2026.
– 19 –
ADULT NUTRITION AND CARE
Our ANC segment grew by 13.9% on a LFL basis in the first half of the year, with our
business in Chinese mainland, the ANZ domestic market and expansion markets delivering
double-digit growth momentum.
Revenue from the Chinese mainland grew by 20.5%, thanks to (i) Swisse’s continued efforts
on premiumisation of product portfolio led by both core and our innovative products, such
as heart health, metabolism, and joint health, (ii) above-market growth across the Douyin
channel and new retail channels, and (iii) phasing effects from the Chinese New Year holidays
in the first quarter of 2026. The broader momentum reflects the unlocking of new structural
sources of demand under our mega-brand strategy and the build-out of a comprehensive
product matrix under the Swisse Plus and Little Swisse sub-brands, expanding the types of
consumers we can reach. Swisse Plus and Little Swisse grew by 18.6% and 60.2% in the first
half of 2026, respectively.
Our strong performance in Chinese mainland was also driven by our ongoing channel
development efforts. Douyin remains a major growth engine, with sales growing by 57.5%,
and Swisse ascended to the No. 3 market position2. We also further strengthened our growth
in new retail channels such as Sam’s Club, with sales through this channel growing by 34.2%.
Sales through our core online cross-border e-commerce (the “CBEC”) channel grew by 20.9%
amid ongoing industry consolidation and despite increased competitive intensity, accounting
for 81.7% of revenue in Chinese mainland. This allowed Swisse to expand its No. 1 position
in the online vitamin, herbal and mineral supplement (the “VHMS”) market in Chinese
mainland3 in the first half of 2026.
In ANZ, we maintained our market leadership through product innovation and channel
expansion, delivering strong 12.2% growth in the Australian domestic market. This was
supported by high-impact innovations, such as Swisse Magnesium Glycinate and the further
expansion of in-demand formats, particularly gummies, and innovative marketing campaigns
designed to engage the new generation of consumers. We also deepened our partnerships with
key retailers in both pharmacy and grocery channels, with particularly strong growth across
independent pharmacy channel banners, online channels and New Zealand. In the first half of
2026, Swisse continued to gain share and maintained its position as Australia’s No. 1 vitamin
and mineral supplements brand across the total market4. Total ANC revenue from the overall
ANZ market decreased by 8.3% year-on-year on a LFL basis, reflecting our strategic choice to
deprioritise the corporate daigou business.
2
According to research statistics by Feigua, an independent data provider, market share data for the past
twelve months ended 30 June 2026.
3
According to research statistics by Early Data, an independent research company, market share data for
the past twelve months ended 30 June 2026.
4
According to research statistics by IQVIA, an independent research company, market share data for the
past twelve months ended 30 June 2026.
– 20 –
Revenue from other territories increased by 20.5% year-on-year on a LFL basis, contributing
7.8% of the total ANC revenue, powered by strong 32.6% LFL growth across our nine
expansion markets in Asia. This was led by strong performances in Thailand, MEI, Indonesia
and Malaysia, rapid growth across digital commerce channels in all markets, product portfolio
expansion, ongoing distribution gains and the launch of Swisse Nutra, a premium beauty
supplement range. We maintained our existing No. 1 positions in the liver health and men’s
health categories in Singapore5. In Italy, we sustained our existing No. 2 position in the beauty
VHMS market6, leveraging our No. 1 position in the hair, skin and nail category.
BABY NUTRITION AND CARE
Our BNC segment accelerated its growth trajectory, demonstrating our renewed competitive
strength and delivering high double-digit year-on-year growth in the first half of 2026.
IMF sales in Chinese mainland grew by 58.0%, led by volume growth, significantly outpacing
the overall IMF market, which saw a 3.5% decline in retail scan sales7. Biostime’s share of
the super-premium IMF segment in Chinese mainland reaching a new all-time high of 20.6%,
compared to 14.8% a year earlier 8. While part of this uplift reflected shifts in consumer
demand amid recent industry developments, our broader momentum was driven by sustained
market-share gains. This structural trend was supported by our strong brand trust and targeted
consumer engagement.
Our continued growth also reflected robust sell-through, disciplined channel execution,
the successful rollout of the first-ever imported IMF with Human Milk Oligosaccharide
(“the HMO”) in Chinese mainland, and the effective implementation of our strategic
initiatives for new mother education and Stage 3 conversion. Our early-stage formulas
continued to see strong momentum, while providing a high-visibility pipeline and solid
foundation for Stage 3 IMF conversion. During the first half of 2026, our Stage 1 and Stage 2
IMFs recorded retail scan sales growth of 68.8% and 41.8%, respectively9.
Outside of Chinese mainland, our IMF business in France experienced strong growth
momentum in the first half of 2026, supported by a spike in demand for Biostime IMFs
amid recent global industry developments. Our shares in organic IMF and goat milk in the
pharmacy channel reached 41.8% and 57.9% respectively10.
5
According to research statistics by Nielsen, an independent research company, market share data for the
past twelve months ended 30 June 2026.
6
According to research statistics by IQVIA, an independent research company, market share data for the
past twelve months ended 30 June 2026.
7
According to research statistics by Nielsen, an independent research company, market share data for the
past twelve months ended 30 June 2026.
8
According to research statistics by Nielsen, an independent research company, market share data for the
past twelve months ended 30 June 2026.
9
According to research statistics by Nielsen, an independent research company, market share data for the
past six months ended 30 June 2026.
10
According to research statistics by GERS, an independent research company, market share data for the
past twelve months ended 30 June 2026.
– 21 –
PET NUTRITION AND CARE
Our PNC segment achieved 4.8% revenue growth on a LFL basis in the first half of 2026,
supported by accelerated growth in the high-margin pet supplements, which offset an expected
sales decline in Chinese mainland as part of our proactive shift to supply localisation.
Sales in the high-margin pet supplements grew by 16.5% as we continued to tap structural
drivers including changing demographics, rising pet populations, and well-established pet
nutrition premiumisation and pet humanisation trends across North America and other
expansion markets.
In North America, sales of Zesty Paws grew by 16.7% on a LFL basis, driven by continued
success across the Amazon and Chewy e-commerce channels, alongside broad distribution
through Walmart, PetSmart, Petco, Tractor Supply, Target, Pet Supplies Plus and Menards.
Zesty Paws remains one of the most recognised pet supplements brands in the United States.
Meanwhile, sales of Solid Gold returned to growth, increasing by 6.3% on a LFL basis as the
brand advanced its product portfolio premiumisation strategy and growth in the e-commerce
channel. As of 30 June 2026, Zesty Paws and Solid Gold were present in more than 23,000
stores and 4,000 stores, respectively, across the United States.
In Chinese mainland, we focused on driving the growth of Solid Gold’s high-margin pet
nutritional food and supplements, which contributed 46.5% of total PNC revenue in Chinese
mainland in the first half of 2026.
We continued to expand our PNC footprint across Europe, Asia and ANZ, with our growing
global reach amplifying our core strengths in premium nutrition and enabling us to capture
rising demand in expansion markets.
OPTIMISING OUR CAPITAL STRUCTURE
We continued to proactively manage and optimise our capital structure in the first half of
2026, with a clear focus on reducing gross debt, extending debt maturity, and strengthening
long-term financial stability.
During the six months ended 30 June 2026, we continued to make strong progress in
deleveraging, reducing our gross debt by over RMB1 billion compared with 31 December
2025. As of 30 June 2026, we had significantly reduced our net leverage ratio to 2.05x,
compared to 3.45x as at 31 December 2025. Building on this momentum, we completed an
additional voluntary prepayment of RMB300 million on our USD term loan following the
period end, further advancing our deleveraging trajectory.
As of 30 June 2026, we maintained a robust cash position of close to RMB2.0 billion,
with RMB-denominated and RMB hedged debts collectively representing 97.8% of total
borrowings. This reflects the proactive management of our funding mix and effectively
mitigates exposure to foreign exchange and external interest rate volatility. We continue to
maintain diversified access to both onshore and offshore funding markets.
– 22 –
In addition, on 5 August 2026, we signed a new facilities agreement in an aggregate amount
equivalent to approximately USD330 million in relation to the refinancing of our term loan
facilities maturing in 2027. Upon drawdown, this transaction is expected to extend our debt
maturity profile, reduce financing costs and further enhance our financial flexibility.
OUTLOOK: CONTINUED GROWTH WITH CONSISTENT UNDERLYING FULLYEAR PROFITABILITY DESPITE MACRO CHALLENGES
In the second half of 2026, we will continue to drive the sustainable growth of our highmargin, fast-growing nutritional supplements and IMF, while delivering a healthy level of
profitability.
Our ANC business is positioned for continued growth across Chinese mainland, ANZ
domestic and our expansion markets. In Chinese mainland, we will continue to invest in our
leading categories to further consolidate Swisse’s leading market position, while expanding
marketing investments to support innovative and strategic product launches, market expansion
and brand-building initiatives to create a clear runway for growth in the second half of 2026
and into 2027. From a channel perspective, we will continue to prioritise penetration into
high-growth channels, particularly Douyin and new retail channels, to further broaden our
consumer reach. In ANZ and expansion markets, we will reinforce our growth momentum and
market leadership through continued product innovation and channel expansion.
In the BNC segment, we expect IMF sales to grow further as we leverage our increased market
share to further develop structural growth drivers. We will continue to invest in marketing
campaigns focused on new mother education across e-commerce and baby-speciality channels
and in product innovations such as our HMO IMFs, while also improving conversion from
early-stage to Stage 3 IMF products.
We expect our PNC segment to maintain its upward trajectory. In North America, Zesty Paws
will continue to advance its omni channel expansion and disruptive category innovation, while
driving Solid Gold’s growth in high margin categories and further accelerate growth across
e-commerce channels. In Chinese mainland, we remain focused on driving the growth of
locally-made Solid Gold’s high-margin pet food and supplements.
Finally, we remain committed to our deleveraging trajectory while maintaining robust liquidity
and a healthy capital structure. We will continue to optimise our debt profile, mitigate foreign
exchange volatility and reinforce our financial resilience to support our sustainable long-term
growth.
– 23 –
MANAGEMENT DISCUSSION AND ANALYSIS
RESULTS OF OPERATION
Revenue
For the six months ended 30 June 2026, the Group’s revenue increased by 23.9% on reported
basis or 23.7% on a like-for-like1 (“LFL”) basis to RMB8,695.9 million as compared with
the same period in 2025. This was mainly driven by the growth across all business segments
– namely Adult Nutrition and Care (“ANC”), Baby Nutrition and Care (“BNC”) and Pet
Nutrition and Care (“PNC”). Revenue from high-margin nutritional supplements2 across all of
the Group’s three business segments achieved year-on-year growth of 13.3% on a LFL basis
and contributed to 60.2% of the Group’s total revenue for the six months ended 30 June 2026.
Six months ended 30 June
Reported
2026
2025
Change
RMB
RMB
million
million
Revenue by product segment
Nutritional Supplements
– VHMS products
– Pet supplements
– Paediatric probiotic and kids
nutritional supplements
Infant formulas
Others3
LFL
Change
2026
% to
revenue
2025
% to
revenue
5,239.1
3,955.0
850.7
4,606.0
3,418.3
760.5
13.7%
15.7%
11.9%
13.3%
14.1%
16.5%
60.2%
45.4%
9.8%
65.6%
48.7%
10.8%
433.4
3,093.0
363.8
427.2
1,970.9
442.3
1.5%
56.9%
–17.7%
1.4%
56.9%
–16.8%
5.0%
35.6%
4.2%
6.1%
28.1%
6.3%
Revenue by business segment
Adult nutrition and care products
Baby nutrition and care products
Pet nutrition and care products
3,973.1
3,632.5
1,090.3
3,438.7
2,501.3
1,079.2
15.5%
45.2%
1.0%
13.9%
45.2%
4.8%
45.7%
41.8%
12.5%
49.0%
35.6%
15.4%
Revenue by geography
Chinese mainland
North America
ANZ
Other territories
6,462.5
956.6
771.7
505.1
4,936.0
862.2
800.7
420.3
30.9%
10.9%
–3.6%
20.2%
30.9%
15.5%
–8.6%
16.8%
74.3%
11.0%
8.9%
5.8%
70.3%
12.3%
11.4%
6.0%
Total
8,695.9
7,019.2
23.9%
23.7%
100.0%
100.0%
1
Like-for-like (“LFL”) basis is used to indicate change of this period compared with same period of
previous year, excluding the impact from foreign exchange changes. For the purpose of preparing of the
unaudited consolidated revenue, the exchange rates adopted were AUD1 = RMB4.8274 and USD1 =
RMB6.8932 for the six months ended 30 June 2026, and AUD1 = RMB4.5771 and USD1 = RMB7.1839
for the corresponding period in 2025, respectively.
2
Nutritional supplements include Swisse VHMS products, pet supplements under Zesty Paws and Solid
Gold brands, Biostime probiotic supplements and Biostime paediatric and kids products.
3
Others include pet food from Solid Gold, baby food and snacks from Good Goût, baby accessories from
Dodie and other skincare products.
– 24 –
Chinese mainland: Strong growth of ANC and BNC segments bolstered by premiumisation,
innovation and market share gains
Revenue from Chinese mainland recorded a year-on-year increase of 30.9% for the six months
ended 30 June 2026. Chinese mainland remained as the Group’s largest market, accounting
for 74.3% of the Group’s total revenue for the six months ended 30 June 2026, compared with
70.3% in the same period of last year.
Revenue from ANC segment in Chinese mainland achieved a strong growth of 20.5%
as compared with the same period of last year, and accounted for 73.0% of the Group’s
total ANC revenue for the six months ended 30 June 2026. The growth was mainly driven
by Swisse’s continuous efforts to premiumise its product portfolio led by both core and
innovative products such as heart health, metabolism and joint health. The growth was also
supported by the Group’s channel development efforts, especially the fast-growing channels
such as Douyin and new retail. Revenue in Douyin and new retail channels recorded yearon-year growth of 57.5% and 34.2%, respectively, in the six months ended 30 June 2026.
The phasing effects from the Chinese New Year holidays in the first quarter of 2026 also
contributed to the revenue growth. In the six months ended 30 June 2026, revenue generated
from CBEC and normal trade channels grew by 20.9% and 18.9%, respectively, contributing
81.7% and 18.3%, respectively, of ANC revenue in Chinese mainland.
BNC segment of Chinese mainland accelerated its growth trajectory and achieved a strong
revenue growth of 47.7% in the six months ended 30 June 2026, comparing with the same
period of last year. Within BNC segment, the revenue from IMF in Chinese mainland for the
six months ended 30 June 2026 grew strongly by 58.0%. This strong growth was mainly driven
by the successful launch of the first-ever imported IMF with Human Milk Oligosaccharide
(HMO) in Chinese mainland, disciplined channel execution, and the effectiveness of the
Group’s strategic priorities in new mother education and Stage 3 conversion. While the
Company observed that the growth was supported by a recent shift in consumer demand amid
recent industry developments in the first half of 2026, the more fundamental driver is its
sustained share – a structural trend reinforced by strong brand trust and targeted consumer
engagement, enabled the Group to take advantage of such shift in consumer demand.
For the six months ended 30 June 2026, the Group recorded a slight increase of 0.9% in
revenue from paediatric probiotic and kids nutritional supplements in Chinese mainland.
The increase was mostly attributed to the expansion of the product portfolio including kids
nutrition powder supplements and innovative probiotics, such as Nasal Comfort and Super
Gold Probiotics. While the growth was offset by the year-on-year decline in sales of probiotic
supplements due to the sector-wide challenges across the supplements business in Chinese
mainland, particularly within the pharmacy channel.
Revenue from PNC segment in Chinese mainland declined by 37.7%, as expected, as
reflecting the Group’s proactive product portfolio transformation aimed at driving the
underlying consumer demand and healthy profitability in the long-term. The Group’s focus
remains on accelerating the growth of Solid Gold’s high-margin pet nutritional food and
supplements, as well as product innovation – demonstrated by the launch of the first ever
“catderived” probiotics range in Chinese mainland during the six months ended 30 June 2026.
The high-margin pet food and supplement products contributed 46.5% of total PNC revenue in
Chinese mainland during the six months ended 30 June 2026.
– 25 –
North America: Ommi-channel growth driven by core and innovative product portfolio and
channel execution
For the six months ended 30 June 2026, revenue generated from North America reached a
growth of 15.5% year-on-year on a LFL basis, and accounted for 11.0% of the Group’s total
revenue. The strong growth was mainly supported by the accelerated growth in the highmargin pet supplements as the Group continued to tap structural drivers including changing
demographics, rising pet populations, and well-established pet nutrition premiumisation and
pet humanisation trends.
Revenue of Zesty Paws maintained strong year-on-year growth of 16.7% on a LFL basis for
the six months ended 30 June 2026, driven by continued success across the Amazon, Chewy
and TikTok, and broad distribution through Walmart, PetSmart, Petco, Tractor Supply, Target,
Pet Supplies Plus and Menards.
Revenue of Solid Gold recorded an increase of 6.3% on a LFL basis for the six months
ended 30 June 2026 as compared with the same period of last year. This growth was mainly
supported by increasing contribution from high-margin pet supplements and growth in
e-commerce channel.
ANZ: Reinforced domestic market leadership through superior product innovation
On a LFL basis, revenue from ANZ domestic market maintained growth at 12.2% in ANC
segment, which was mainly driven by high-impact innovations, such as Swisse Magnesium
Glycinate and the further expansion of in-demand formats, particularly gummies, and
innovative marketing campaigns designed to engage the new generation of consumers. While
revenue from total ANZ market decreased by 8.6% year-on-year on a LFL basis for the
six months ended 30 June 2026, reflecting the Group’s strategic choice to deprioritise the
corporate Daigou business. In the six months ended 30 June 2026, revenue from domestic and
export sales contributed to 83.7% and 16.3% of total ANZ revenue, respectively.
Other territories: Strong growth momentum continued in expansion markets
Revenue contributed from other territories increased by 16.8% on a LFL basis for the six
months ended 30 June 2026 as compared with the same period of last year. In particular,
the Group’s expansion markets in Asia, including Thailand, MEI (Middle East and India),
Indonesia and Malaysia, delivered strong growth. The Group sustained its market share
rankings in most of these markets through the expansion of its product portfolio and ongoing
distribution gains. The Group’s IMF sales in France also benefited from a spike in demand for
Biostime IMF due to new industry developments during the six months ended 30 June 2026.
Gross profit and gross profit margin
In the first half of 2026, the Group recorded gross profit of RMB5,686.0 million, representing
an increase of 29.5% as compared with the same period of last year. The Group’s gross profit
margin increased from 62.5% in the first half of 2025 to 65.4% in the first half of 2026, thanks
to gross profit margin improvement across all three business segments driven by operating
leverage, product portfolio premiumisation and supply chain excellence.
– 26 –
The gross profit margin of the ANC segment increased from 67.5% in the first half of 2025
to 70.2% in the first half of 2026, primarily driven by the optimisation of sourcing costs,
reduction of stock provision for slow-moving products, as well as favourable changes in
product mix through product portfolio premiumisation, and channel mix.
The gross profit margin of the BNC segment increased from 57.3% in the first half 2025
to 61.5% in the first half of 2026, mainly resulting from the decreased stock provision for
slow-moving products, while partially offset by the increased sourcing costs of certain key
ingredients.
The gross profit margin of PNC segment increased from 58.7% in the first half of 2025
to 61.1% in the same period of this year. The increase was mainly due to the favorable
product mix towards higher revenue contribution from high-margin pet nutritional food and
supplements products.
Other income and gains
Other income and gains amounted to RMB36.3 million for the six months ended 30 June 2026.
Other income and gains primarily consisted of gains on sales of raw materials and scraps of
RMB11.2 million, bank interest income of RMB7.5 million and others.
Selling and distribution expenses
Excluding depreciation of property, plant and equipment and right-of-use assets, and
amortization of intangible assets (“D&A”), selling and distribution expenses increased by
15.0% to RMB3,315.5 million for the six months ended 30 June 2026, as compared with
same period of 2025. Selling and distribution expenses excluding D&A as a percentage of the
Group’s revenue decreased from 41.1% in the first half of 2025 to 38.1% in the first half of
2026 mainly benefited from a favourable business segment mix primarily driven by spending
efficiency improvement and marketing investment phasing in the BNC segment.
ANC
Selling and distribution expenses of ANC business amounted to RMB1,639.8 million for
the six months ended 30 June 2026, representing an increase of 13.8% as compared with the
same period of last year. Selling and distribution expenses of ANC business as a percentage
of the Group’s revenue from ANC business decreased slightly from 41.9% in the first half of
2025 to 41.3% in the first half of 2026, mainly thanks to the efficiency improvement which
was partially offset by the channel mix change in Chinese mainland market and strategic
investment in new expansion markets mainly in Asia.
Advertising and marketing expense of ANC business as a percentage to the Group’s ANC
revenue decreased slightly from 34.6% in the first half of 2025 to 34.3% in the first half of
2026. The selling and distribution expenses other than advertising and marketing expense of
ANC business as a percentage to its revenue decreased slightly from 7.3% in the first half of
2025 to 7.0% in the first half of 2026.
– 27 –
BNC
Selling and distribution expenses of BNC business amounted to RMB1,163.6 million for the
six months ended 30 June 2026, representing an increase of 22.2% as compared with the same
period of last year. Selling and distribution expenses of BNC business as a percentage of the
Group’s revenue from BNC business decreased from 38.1% in the first half of 2025 to 32.0%
in the first half of 2026. The significant decrease was mainly driven by the Group’s ongoing
efforts to enhance spending efficiency and phasing impact. Higher marketing and promotional
investment are planned in the second half of 2026 to accelerate the new product rollout.
Advertising and marketing expense of BNC business as a percentage of its revenue decreased
from 14.2% in the first half of 2025 to 11.0% in the first half of 2026, mainly due to the high
base of investment in the first half of 2025 allocated to marketing campaigns for the new ‘GB’
IMF products. Selling and distribution expenses other than advertising and marketing expense
of BNC business as a percentage of revenue decreased from 23.9% in the first half of 2025 to
21.0% of the same period of 2026 thanks to the operating leverage and the Group’s ongoing
efforts to enhance spending efficiency.
PNC
Selling and distribution expenses of PNC business increased by 4.4% to RMB512.0 million
for the six months ended 30 June 2026, as compared with the same period of last year. Selling
and distribution expenses of PNC business as a percentage of its revenue increased from
45.4% for the six months ended 30 June 2025 to 47.0% for the same period of 2026, mainly
due to the additional investment required to support the new products launch and geography
expansion including Europe, Asia and ANZ.
Advertising and marketing expense of PNC business as percentages of its revenue increased
from 13.2% for the six months ended 30 June 2025 to 21.3% for the six months ended 30
June 2026. The increase was mainly due to the additional investment required to support the
launch of new products, particularly the new high-margin pet nutritional food and supplement
products. The selling and distribution expenses other than advertising and marketing expense
of PNC business as a percentage to its revenue decreased from 32.2% in the first half of
2025 to 25.7% in the first half of 2026, which was mainly driven by spending efficiency
improvement and the phasing of investments.
Administrative expenses
Administrative expenses increased by 11.4% from RMB398.5 million for the six months
ended 30 June 2025 to RMB443.8 million for the six months ended 30 June 2026. While
administrative expenses as a percentage of the Group’s revenue decreased from 5.7% in the
first half of 2025 to 5.1% in the first half of 2026 thanks to the Group’s continuous efforts on
operating leverage and efficiency improvement.
– 28 –
Other expenses
Other expenses for the six months ended 30 June 2026 amounted to RMB404.1 million. Other
expenses mainly included research and development (“R&D”) expenditure of RMB107.9
million, net fair value losses on derivative financial instruments of RMB154.9 million, net
foreign exchange losses of RMB82.4 million, net fair value losses on other non-current
financial assets of RMB37.9 million and others.
During the six months ended 30 June 2026, R&D expenditure increased by 12.5% as
compared with the same period of last year, which was primarily due to higher investment in
innovation and product development to support the launch of new products. R&D expenditure
as a percentage of the Group’s revenue decreased from 1.4% for the six months ended 30 June
2025 to 1.2% for the six months ended 30 June 2026.
The non-cash net fair value losses on derivative financial instruments of RMB154.9 million
consisted of: (i) RMB87.5 million of fair value losses on the cross currency swap (“CCS”)
and cross currency interest rate swap (“CCIRS”) agreements for the Group’s long-term USD
debts. Since such CCS and CCIRS are revaluated on each reporting date, the losses mainly
represented RMB’s appreciation against USD on the reporting date; (ii) RMB45.7 million
of fair value losses on the forward contracts mainly designated to hedge EUR exposures
against RMB arising from day-to-day operating activities. Similar to the CCS and CCIRS,
such forward contracts are also revaluated on each reporting date, and the losses represented
RMB’s appreciation against EUR on the reporting date; and (iii) RMB21.7 million of fair
value losses on the early redemption option embedded in the senior notes due in 2028.
The net foreign exchange losses of RMB82.4 million mainly represented non-cash losses from
the revaluation on intragroup loans.
The net fair value losses on other non-current financial assets of RMB37.9 million mainly
represented non-cash losses from the fair value change of the existing equity investments held
by New H2 Limited.
EBITDA and Adjusted EBITDA
Adjusted EBITDA achieved a strong growth by 71.9% to RMB1,891.9 million for the six
months ended 30 June 2026, comparing with the same period of 2025. Adjusted EBITDA
margin for the first half of 2026 improved significantly from 15.7% for the six months ended
30 June 2025 to 21.8% for the same period of 2026. The significant improvement in adjusted
EBITDA margin was mainly attributable to the continued operating leverage, product portfolio
premiumisation and the Group’s prudent marketing investments during the period, ahead of a
more active brand-building and promotional activities planned for the second half of 2026 to
accelerate the new product rollout and market expansion.
EBITDA for the six months ended 30 June 2026 increased by 53.3% from RMB1,033.1
million for the six months ended 30 June 2025 to RMB1,583.3 million.
– 29 –
The adjusted EBITDA was arrived at by reconciling the non-recurring or non-cash items from
EBITDA as set out below:
Six months ended 30 June
2026
2025
RMB million
RMB million
EBITDA
Reconciled by:
Non-cash items*:
(1) Net fair value losses on derivative financial
instruments
(2) Net foreign exchange losses/(gains) mainly from the
revaluation on intragroup loans
(3) Net fair value losses/(gains) on other non-current
financial assets
(4) Share of losses of associates
Non-recurring items*:
(5) One-time consulting fee for group entity structure
optimisation
Adjusted EBITDA
*
1,583.3
1,033.1
154.9
74.0
82.4
(24.4)
37.9
33.4
(5.5)
13.5
–
10.0
1,891.9
1,100.7
Either non-recurring or non-cash items is to be adjusted only if the amount is equal to or greater than
RMB10 million.
Finance costs
During the six months ended 30 June 2026, the Group’s finance costs decreased by 46.2%
from RMB579.5 million for the six months ended 30 June 2025 to RMB311.9 million for the
same period in 2026. The finance costs for the six months ended 30 June 2026 included (i)
RMB307.1 million of interest on the interest-bearing bank loans, senior notes and guaranteed
bonds, which decreased by 12.6% year-on-year; (ii) RMB4.9 million of interest on lease
liabilities.
As the Group has entered into certain cross currency swaps and cross currency interest rate
swaps to hedge its interest rate risk and foreign currency risk, respectively, the normalised
interest on the interest-bearing bank loans, senior notes and guaranteed bonds was RMB236.4
million for the six months ended 30 June 2026, which decreased by 19.4% from RMB293.3
million for the same period of last year. The implied annual interest expense margin4 (including
the benefit of the above-mentioned hedges) was 5.65% for the six months ended 30 June 2026,
which decreased from 5.96% for the year ended 31 December 2025.
4
The implied annual interest expense margin is calculated as normalised interest expense for the last twelve
months ended 30 June including the benefit of hedge arrangements divided by the average gross interestbearing debt over the same period.
– 30 –
Income tax expense
Income tax expense increased by 120.1% from RMB235.3 million for the six months ended
30 June 2025 to RMB517.9 million for the six months ended 30 June 2026. The effective
tax rate on a pro forma basis decreased from 40.0% in the first half of 2025 to 36.0% in the
same period this year, after adjusting for non-deductible and non-cash items on profit before
tax, including the net foreign exchange losses/(gains), net fair value losses on derivative
financial instruments and other non-current financial assets, share of losses of associates, onetime premium paid for the tender offer and early redemption of the senior notes due in 2026,
and the related non-cash write-off of unamortised transaction costs. On a reported basis, the
effective tax rate decreased significantly from 76.8% in the first half of 2025 to 45.9% in the
first half of 2026.
Net profit and Adjusted net profit
The adjusted net profit was arrived at by reconciling the non-recurring or non-cash items from
net profit as set out below:
Six months ended 30 June
2026
2025
RMB million
RMB million
Net profit
Reconciled by:
EBITDA adjusted items as listed above
Non-cash items*:
One-time premium paid for the tender offer and
early redemption of the senior notes due in 2026,
and the related non-cash write-off of unamortised
transaction costs
Adjusted net profit
*
610.6
71.0
308.6
67.6
–
224.4
919.2
363.0
Either non-recurring or non-cash items is to be adjusted only if the amount is equal to or greater than
RMB10 million.
Non-IFRS financial measures
To supplement the Group’s consolidated financial statements which are prepared in
accordance with IFRS, the Group also use adjusted EBITDA and adjusted net profit as
additional financial measures, which are not required by, or presented in accordance with
IFRS. The Group believes that these non-IFRS financial measures facilitate comparisons
of operating performance from period to period and company to company by eliminating
potential impacts of items that the Company’s management does not consider to be indicative
of its operating performance such as certain non-cash or non-recurring items. The use of these
non-IFRS financial measures has limitations as an analytical tool, and one should not consider
them in isolation from, or as a substitute for analysis of, the Group’s results of operations or
financial conditions as reported under IFRS. In addition, these non-IFRS financial measures
may be defined differently from similar terms used by other companies.
– 31 –
LIQUIDITY AND CAPITAL RESOURCES
Operating activities
For the six months ended 30 June 2026, the Group recorded net cash generated from operating
activities of RMB1,695.1 million, resulting from pre-tax cash generated from operations of
RMB1,891.1 million, minus income tax paid of RMB196.0 million. The cash conversion rate
for the six months ended 30 June 2026, calculated as pre-tax cash generated from operations
divided by adjusted EBITDA, was 100.0%. A negative change of RMB17.9 million in working
capital was recorded, mainly resulted from: (i) an increase in trade receivables by RMB234.3
million mainly due to the increase in sales; (ii) an increase in prepayments, other receivables
and other assets by RMB37.1 million; (iii) a slight increase in inventories, net of write-down
of inventories to net realisable value, by RMB16.0 million; and (iv) the above negative impact
was partially offset by an increase in other payables and accruals of RMB202.7 million, an
increase in trade and bills payables of RMB61.4 million and others.
Investing activities
For the six months ended 30 June 2026, net cash flows used in investing activities amounted
to RMB112.1 million, primarily resulted from purchases of property, plant and equipment and
intangible assets of RMB38.4 million, the increase in time deposits with original maturity of
three months or more when acquired of RMB80.2 million, partially offset by interest received
of RMB7.5 million.
Financing activities
For the six months ended 30 June 2026, net cash flows used in financing activities amounted
to RMB1,366.5 million, primarily related to the repayment of interest-bearing bank loans of
RMB1,388.0 million, the interest paid for borrowings of RMB271.4 million and others. The
above cash outflows were partially offset by the proceed from new interest-bearing bank loans
of RMB250.0 million and others.
Cash and bank balances
As of 30 June 2026, cash and cash equivalents and time deposits as stated in the interim
condensed consolidated statement of financial position amounted to RMB1,976.5 million.
Borrowings
As of 30 June 2026, the Group’s outstanding carrying amount of its borrowings amounted to
RMB7,581.6 million, including current portion of RMB1,803.0 million. The carrying amount
of borrowings included (i) RMB5,069.5 million of interest-bearing bank loans, including
current portion of RMB1,308.5 million; (ii) RMB2,098.5 million of senior notes, including
current portion of RMB80.9 million; and (iii) RMB413.6 million of guaranteed bonds, all of
which was current.
– 32 –
The Group’s gearing ratio decreased from 45.8% as of 31 December 2025 to 38.9% as of
30 June 2026, calculated by dividing the sum of the carrying amount of the borrowings by
total assets. As of 30 June 2026, the net leverage ratio significantly decreased from 3.45x
as of 31 December 2025 to 2.05x, calculated as the following table. The strong progress
in deleveraging was primarily driven by the voluntary prepayment of over RMB1.2 billion
(equivalent) on the Group’s USD term loan, supported by its strong internal liquidity which
was enhanced by incrementally low-cost RMB borrowings.
Gross debt5
Less: Cash and cash equivalents and time deposit
Net debt
Divided by: Adjusted EBITDA6
Net leverage ratio
30 June
2026
RMB million
31 December
2025
RMB million
7,790.2
1,976.5
5,813.7
2,841.7
2.05x
8,790.2
1,709.0
7,081.2
2,050.5
3.45x
Working capital
Advance payment is normally required for the sales to business customers in Chinese
mainland, except for limited circumstances. The Group usually allows credit sales in overseas
markets outside Chinese mainland, with average credit terms ranging from 30 to 90 days from
the end of month. The Group’s suppliers generally grant a credit period between 30 and 90
days.
The Group seeks to maintain strict controls over outstanding receivables and creditors to
minimise credit risk. The average turnover days for trade receivables decreased from 27 days
for the six months ended 30 June 2025 to 20 days for the six months ended 30 June 2026. The
decrease mainly resulted from the higher revenue contribution from Chinese mainland. The
average turnover days of trade and bills payables decreased slightly from 63 days for the six
months ended 30 June 2025 to 62 days for the six months ended 30 June 2026.
The inventory turnover days decreased from 131 days for the six months ended 30 June 2025
to 118 days for the six months ended 30 June 2026. The inventory turnover days of ANC
products decreased from 136 days for the six months ended 30 June 2025 to 107 days for the
six months ended 30 June 2026. The inventory turnover days of BNC products decreased from
122 days for the six months ended 30 June 2025 to 113 days for the six months ended 30 June
2026. The decrease in the inventory turnover days of ANC and BNC products was primarily
due to the higher-than-expected sales. The inventory turnover days of PNC products increased
from 142 days for the six months ended 30 June 2025 to 166 days for the six months ended 30
June 2026. The increase in PNC inventory turnover days was mainly due to strategic inventory
build-up to support new market expansion and ensure supply chain continuity.
5
The gross debt as of 30 June 2026 and 31 December 2025 are calculated with the outstanding principal of
debt instruments being converted to RMB with constant FX rates as the debt drawdown date.
6
Adjusted EBITDA for the twelve months ended 30 June 2026 and the year ended 31 December 2025.
– 33 –
SIGNIFICANT BUSINESS DEVELOPMENT AFTER THE END OF THE REPORTING
PERIOD
Capital Structure Optimisation
The Group continued to optimise its capital structure through active debt management and to
demonstrate its ongoing commitment to deleveraging. On 5 August 2026, the Group signed
a new term loan facilities agreement in the amount equivalent to approximately US$320.0
million7, primarily to refinance its existing term loan facilities due in 2027. The refinancing is
expected to extend the Group’s debt maturity profile, reduce finance costs and further enhance
its financial flexibility. On 13 August 2026, the Group voluntarily prepaid approximately
RMB300 million (equivalent) in respect of its USD term loan, resulting in a further reduction
in the Group’s gross debt.
Update On Tax Audit on Biostime Healthy Australia Pty Ltd (“BHA”)
As disclosed in the Company’s Annual Report for the year ended 31 December 2025, BHA, a
subsidiary of the Company, has undergone an audit (the “BHA Tax Audit”) conducted by the
Australian Tax Office (the “ATO”) in respect of the value of intellectual property and other
assets transferred as part of the Groupwide integration initiatives in 2018, for which BHA paid
AUD19 million of tax under the Australian capital gains tax (the “CGT”) rules.
Based on the conclusion of the BHA Tax Audit, on 10 April 2025, the ATO issued official
notices of amended assessment requesting: (i) AUD234.5 million of primary tax payable by
BHA in respect of the year ended 31 December 2018; (ii) AUD55.2 million of interest and (iii)
AUD117.3 million penalty payable by BHA.
In June 2025, BHA formally objected to the ATO’s amended assessments to officially dispute
these amounts (the “Objection”). On 4 July 2025, having considered BHA’s proposals
regarding payment arrangement, the ATO confirmed that it required BHA to provide a
cash deposit of AUD104 million to the ATO by 15 July 2025, in accordance with the ATO
administrative practice for disputed tax debts. Consequently, such cash deposit was made on
15 July 2025 and recorded as deposits in BHA’s financial statements as of 31 December 2025
and 30 June 2026. No further deposit is required until the final conclusion of this matter.
BHA and its representatives have actively engaged with the ATO’s objection team to discuss
technical areas of disagreement and other developments. On 3 July 2026, the ATO issued a
written decision substantially disallowing (and allowing in part) BHA’s Objection (resulting
in a reduction in primary tax from AUD234.5 million to AUD208.1 million and a reduction in
penalty from AUD117.3 million to AUD104.0 million) (the “Objection Decision”). In doing
so, the ATO has maintained its reliance on its primary position to substitute the value of the
transferred assets under the CGT rules, as well as an alternative position under the transfer
pricing rules.
7
A revolving credit facility in the amount equivalent to approximately US$10.0 million was also made
available under the new term loan facilities agreement.
– 34 –
BHA has been and will continue vigorously defending its position. On 10 July 2026, BHA
filed a Notice of Appeal in the Federal Court of Australia (the “Court”) to formally initiate
legal proceedings in relation to the Objection Decision insofar as it concerns ATO’s tax
assessment. On 16 July 2026, BHA filed an application in the Administrative Review Tribunal
(the “Tribunal”) to seek a review of the Objection Decision insofar as it concerns penalties
and interest. A hearing date for each proceeding is yet to be set by the Court and the Tribunal,
respectively.
BHA continues to be assisted by tax litigation lawyers and preeminent counsel. At this time,
in the opinion of the Directors, BHA does not consider that it is probable that there will be a
final outflow of funds in relation to the matters in dispute. In the event that BHA is successful
in the dispute, BHA will be entitled to a refund of the deposit plus interest.
INTERIM DIVIDEND
After taking full consideration of the Group’s financial position, net cash flow and capital
expenditures, the Board has resolved to declare an interim dividend of HKD0.82 per ordinary
share, representing approximately 50% of the Group’s adjusted net profit for the period of
six months ended 30 June 2026. The interim dividend will be paid on or about Monday, 12
October 2026 to the shareholders whose names appear on the register of members of the
Company on Wednesday, 16 September 2026.
CLOSURE OF REGISTER OF MEMBERS
The register of members of the Company will be closed from Monday, 14 September 2026
to Wednesday, 16 September 2026, both days inclusive, during which period no transfer
of shares can be registered. The record date is Wednesday, 16 September 2026. In order to
qualify for the interim dividend, all transfers accompanied by the relevant share certificates
must be lodged with the Company’s Hong Kong branch share registrar and transfer office,
Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor,
Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than
4:30 p.m. on Friday, 11 September 2026.
CORPORATE GOVERNANCE CODE
The Company’s corporate governance practices are based on the principles and code
provisions as set out in the Corporate Governance Code (the “CG Code”) contained in Part 2
of Appendix C1 of the Rules Governing the Listing of Securities (the “Listing Rules”) on The
Stock Exchange of Hong Kong Limited (the “Stock Exchange”). The Company has complied
with all the code provisions contained in the CG Code for the six months ended 30 June 2026.
The Company will continue to enhance its corporate governance practices appropriate to the
conduct and growth of its business and to review such practices from time to time to ensure
that they comply with the CG Code and align with the latest developments.
– 35 –
MODEL CODE FOR SECURITIES TRANSACTIONS
The Company has adopted its own code of conduct regarding Directors’ dealings in the
Company’s securities (the “Company Code”) on terms no less exacting than the Model Code
for Securities Transactions by Directors of Listed Issuers (the “Model Code”) as set out in
Appendix C3 to the Listing Rules.
Specific enquiry has been made of all the Directors and all the Directors have confirmed that
they have complied with the Company Code and the Model Code during the six months ended
30 June 2026.
The Company has also established written guidelines (the “Employees Written Guidelines”)
on terms no less exacting than the Model Code for securities transactions by employees who
are likely to be in possession of unpublished inside information of the Company.
No incident of non-compliance of the Employees Written Guidelines by the relevant
employees was noted by the Company during the six months ended 30 June 2026.
In case when the Company is aware of any restricted period for dealings in the Company’s
securities, the Company will notify its Directors and relevant employees in advance.
AUDIT COMMITTEE
The audit committee of the Company (the “Audit Committee”) was established on 25
November 2010 in compliance with Rules 3.21 and 3.22 of the Listing Rules and with
written terms of reference in compliance with the CG Code. The Audit Committee consists
of three members, namely, Professor Ding Yuan, Mr. Tan Wee Seng and Mr. Luo Yun, all of
whom are non-executive Directors and the majority of whom are independent non-executive
Directors. Professor Ding Yuan, who possesses the appropriate professional qualifications or
accounting or related financial management expertise, was appointed as the chairman of the
Audit Committee.
The Audit Committee is mainly responsible for making recommendations to the Board on
the appointment, re-appointment and removal of the external auditors and to approve the
remuneration and terms of engagement of the external auditors; reviewing the interim and
annual reports and accounts of the Group; and overseeing the Group’s financial reporting
system, internal control system and risk management system and associated procedures.
REVIEW OF INTERIM FINANCIAL STATEMENTS
Disclosure of financial information in this interim results announcement complies with
Appendix D2 of the Listing Rules. The Audit Committee has held meetings to discuss the
internal controls and financial reporting matters of the Company, including the review of the
interim report and the unaudited interim condensed consolidated financial statements of the
Group for the six months ended 30 June 2026.
– 36 –
The interim condensed consolidated financial statements for the six months ended 30 June
2026 have not been audited but have been reviewed by the Company’s independent auditor,
Ernst & Young, in accordance with Hong Kong Standard on Review Engagements 2410
“Review of Interim Financial Information Performed by the Independent Auditor of the
Entity” by the Hong Kong Institute of Certified Public Accountants.
PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES
Neither the Company, nor any of its subsidiaries has purchased, sold or redeemed any of the
Company’s listed securities (including sale of treasury shares, if any) during the six months
ended 30 June 2026.
PUBLICATION OF INTERIM RESULTS ANNOUNCEMENT AND INTERIM
REPORT
This interim results announcement is also published on the websites of the Company
(www.hh.global) and the Stock Exchange (www.hkexnews.hk). The interim report for the
six months ended 30 June 2026 containing all the information required by Appendix D2 to
the Listing Rules will be despatched to the shareholders of the Company (if requested) and
available on the above websites in due course.
By order of the Board of
Health and Happiness (H&H) International Holdings Limited
Luo Fei
Chairman
Hong Kong, 25 August 2026
As at the date of this announcement, the executive directors of the Company are Mr. Luo Fei
and Mr. Wang Yidong; the non-executive directors of the Company are Mrs. Laetitia Albertini,
Dr. Zhang Wenhui, Mr. Luo Yun and Mrs. Mingshu Zhao Wiggins; and the independent nonexecutive directors of the Company are Mr. Tan Wee Seng, Mrs. Lok Lau Yin Ching and
Professor Ding Yuan.
– 37 –